Angiogenesis Inhibitor and Simulator Market Outlook:
Angiogenesis Inhibitor and Simulator Market size was valued at USD 8.4 billion in 2024 and is predicted to reach USD 23.2 billion by the end of 2037, rising at a CAGR of 8.9% during the forecast period from 2025 to 2037. In 2025, the industry size of angiogenesis inhibitors and simulators is estimated at USD 9.2 billion.
The global patient case in angiogenesis inhibitor and simulator therapies continues to rise, with an increase in cancer incidence and age-related ophthalmic disorders. Based on the WHO report, nearly 10.2 million cancer-related deaths occurred in 2022, with colorectal, lung, and breast cancers especially seen in cases requiring anti-angiogenic treatment. The NCI reports that over 2 million new cancer cases are registered yearly in the U.S. alone, sustaining the demand for VEGF inhibitors and monoclonal antibodies. The supply chain for these medicines relies on active pharmaceutical ingredients (APIs) from specialist manufacturers, with China and India dominating API manufacturing, followed by formulation and fill-finish procedures in the U.S. and Europe.
Angiogenesis inhibitors and simulators market’s global trade based on the U.S. International Market Trade Commission in 2023, is highly influenced by the U.S, EU, and China markets, with the U.S. importing APIs worth 2.3 billion yearly. Meanwhile, Switzerland and Germany lead in finished drug exports, making a supply worth 357 billion for cancer research in 2024. Besides, the consumer price index (CPI) for anti-angiogenic drugs has grown by 6.7% since 2022, owing to inflation and supply chain issues with clinical-grade raw ingredients. According to the FDA Drug Shortage Database for 2024, assembly lines for biologics are experiencing bottlenecks caused by sterility compliance delays, thus increasing average production lead times by 18.3%.
Angiogenesis Inhibitor and Simulator Market Growth Drivers and Challenges:
Growth Drivers
- Government healthcare spending & reimbursement policies: The primary market driver for angiogenesis inhibitor and simulator market plays a major role in government healthcare expenditure with Medicare reaching USD 3.4 billion in 2023. This growth is from the expanded coverage for ophthalmology and oncology, especially in anti-VEGF therapies. Further, the angiogenesis inhibitor and simulator market is stimulated with the FDA’s accelerated approval pathway, with 13 new angiogenesis drugs receiving rapid designation in 2024. This has resulted in reducing the development period by almost 30.5%. Hence, these regulatory efficiencies are expected to maintain a strong market growth by the end of 2030.
- Growing patient populations and disease burden: The number of patient cases registered globally has significantly risen, which is seen especially in developed nations. The number of cancer cases in Europe is projected to be 4.9 million, thereby requiring angiogenesis inhibition by 2025, and also representing a 41% increase over the past decade. The patient registration cases in Japan are increasing, and approximately 1.3 million patients are now diagnosed with wet AMD, which is a crucial indication for anti-angiogenic therapy. Therefore, these epidemiological trends are driving continued demand in both the cancer and ophthalmology areas.
Key Market Dynamics for Historical Patient Growth
The angiogenesis inhibitor and simulator market has been shaped by decades with the increase in patient cases. This is mainly driven by the rising cancer incidence, improved diagnostic capabilities, and ophthalmic disorders. Over the past decade, emerging nations have experienced substantial growth in patients, directly affecting manufacturing strategies, drug development, and reimbursement policies. Germany and France have shown steady growth due to the aged population and strong insurance coverage, while Australia and Spain have seen moderate growth with a smaller patient base.
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
2014 Patients (Million) |
2024 Patients (Million) |
Growth Rate (%) |
Key Market Driver |
|---|---|---|---|---|
|
USA |
1.9 |
3.6 |
94.2% |
Oncology + AMD approvals |
|
Germany |
0.6 |
1.4 |
94.1% |
Aging population + biosimilar adoption |
|
France |
0.56 |
1.2 |
108.1% |
Expanded reimbursement (Lucentis/Avastin) |
|
Spain |
0.33 |
0.64 |
111% |
Teleophthalmology expansion |
|
Australia |
0.25 |
0.47 |
117% |
High govt. healthcare spend |
|
Japan |
1.4 |
2.42 |
100.2% |
NHI coverage for wet AMD |
|
India |
0.8 |
2.4 |
229.1% |
Local biosimilar production |
|
China |
1.2 |
3.81 |
245.6% |
Insurance coverage (NRDL inclusions) |
Key Feasibility Models for Angiogenesis Inhibitor and Simulator Market Expansion
The angiogenesis inhibitor and simulator market of angiogenesis inhibitors and simulators has been reshaped by expansion strategies with an increase in revenue since manufacturers have adopted partnerships, telemedicine integration, and biosimilar products. For instance, in India, the NHP report states that collaboration between suppliers and hospitals has increased revenue by 12.3% by enhancing surging rural accessibility. On the other hand, according to the NHSA report, in China, NRDL insurance inclusions boosted sales by 18.3% yearly since 2020.
Feasibility Models for Revenue Growth
|
Strategy |
Region |
Revenue Impact |
Key Statistic |
|---|---|---|---|
|
Hospital Partnerships |
India |
+12.2% (2022–2024) |
1,210+ clinics added |
|
NRDL Insurance Coverage |
China |
+18.1% CAGR |
22 drugs reimbursed since 2020 |
|
Medicare Policy Expansion |
USA |
+9.2% (2023) |
451K additional patients covered |
|
EU Cross-Border Healthcare |
Germany |
+15.5% patient reach |
9 new EU-wide treatment centers |
|
Telemedicine Integration |
Australia |
+21% rural uptake |
151K remote consultations (2024) |
Challenges
- Supply chain vulnerabilities: The supply chain for angiogenesis treatment is extremely fragile, particularly in API sourcing and manufacturing compliance. Export controls in China delayed 18.2% of the API supply in 2023, which leads to production shutdown. Similarly, FDA eliminated nearly 13% of injectable batches in 2024 due to Good Manufacturing Practice (GMP) and sterility lapses. These delays in products affect the overall operational costs and compromise patient access. Therefore, such liabilities demonstrate the requirement of diversified supply networks and stringent quality control systems.
- Competition from biosimilars: The angiogenesis inhibitor and simulator market is driving a significant price reduction due to the rapid transformation of biosimilar competition. In the EU, the price of bevacizumab has been reduced by 52% in 2020, owingto the adoption of biosimilars. However, the U.S. market has only achieved 16% market penetration due to physician hesitancy and lack of education. To address this scenario, there is the need for balanced policies that foster biosimilar uptake while ensuring reasonable return for originator drugs in complex biologic therapy segments.
Angiogenesis Inhibitor and Simulator Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.9% |
|
Base Year Market Size (2024) |
USD 8.4 billion |
|
Forecast Year Market Size (2037) |
USD 23.2 billion |
|
Regional Scope |
|
Angiogenesis Inhibitor and Simulator Market Segmentation:
Application Segment Analysis
In application, the oncology segment is expected to gain 55.2% of market share by 2037 with the rise in the cancer burden globally. The projected increase in colorectal cancer cases by 30.2% during the forecast timeline is the key growth driver for the oncology segment. Additionally, combination therapies such as anti-VEGF drugs combined with immunotherapy improve the survival rates, thus boosting the demand. The expansion of the segment is supported by an increase in R&D investments in next-gen angiogenesis inhibitors, thereby targeting treatment-resistant tumors and ensuring the angiogenesis inhibitor and simulator market leadership is sustained in the upcoming years.
Type Segment Analysis
In the type segment, monoclonal antibodies such as ranibizumab and bevacizumab will account for 42.2% of the angiogenesis inhibitor and simulator market share by the end of 2037, owing to their demonstrated efficacy in ophthalmology and cancer. Also, Japan’s NHI and U.S. Medicare are boosting market penetration and are expanding their reimbursement policies. Biosimilar adoption supports the segment’s growth which is expected to minimize the treatment costs by 25.4%, thus enhancing accessibility. Further, the dominance of monoclonal antibodies is reinforced by their targeted mechanism, reducing the off-target effects and improving patient outcomes in colorectal cancer and wet AMD treatments.
Our in-depth analysis of the angiogenesis inhibitor and simulator market includes the following segments:
|
Type |
|
|
Application |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAngiogenesis Inhibitors and Simulators Market Regional Analysis:
North America Market Insights
North America is expected to be a leader in the angiogenesis inhibitor and simulator market by 2037 and is projected to have a market share of 42.4%, by its strong healthcare infrastructure, development investments significant research, and high occurrence of cancer and diabetic retinopathy. In 2023, U.S. and Canada are the key contributors with the U.S. alone accounting for 36.5% of the angiogenesis inhibitor and simulator market share based on market growth in 2022 and 2026. The market has also surged by technological advancements including novel monoclonal antibodies and tyrosine kinase inhibitors offering enhanced efficacy and safety measurements.
The angiogenesis inhibitors and simulators market in the U.S. has been on a continuous rise mainly in oncology and ophthalmology indications. In 2023, the U.S. has allocated 8% of its budget to healthcare which is equivalent to USD 5.5 billion for angiogenesis-based treatments. Federal programs such as Medicare and Medicaid readily cover these therapies. Furthermore, Medicare has allocated USD 1.3 billion for angiogenesis therapy by 2024, with reimbursement regulations growing to cover more than 12% of patients. The U.S. market is shifting toward improved treatment results and patient quality care through combination treatments and individualized medicine.
The angiogenesis inhibitors and stimulators market in Canada is characterized by a collaborative provincial and federal healthcare system to ensure access to advanced treatment for all individuals in the nation. In 2023, the federal healthcare budget in Canada has allocated nearly 8.5%, of which is USD 3.5 billion has been provided to angiogenesis therapies, marking a 14% rise since 2020. Companies such as Canadian Healthcare Association and Innovative Medicines Canada are instrumental in promoting R&D in this sector. Hence, the Canada market is experiencing a rise in the adoption of biosimilar and novel drug delivery systems that is expected to rise treatment affordability and accessibility.
Europe Market Insights
Europe is the fastest growing region for market of angiogenesis inhibitors and stimulators and expecting to have a global share of 30.2% and CAGR 5.4% in 2037. The angiogenesis inhibitor and simulator market for angiogenesis inhibitors and stimulators in Europe is set to grow high from 2023 to 2032. Initially, it was worth around USD 4.7 billion in 2023 and is projected to hit USD 8.3 billion by 2032, reflecting a robust growth rate. This growth is formally driven by the increase in disease occurrence such as diabetic retinopathy, cancer, and age-related macular degeneration, which necessitate advanced therapeutic interventions. Various factors including monoclonal antibody therapies, enhanced drug delivery systems, and supportive healthcare policies lead to the angiogenesis inhibitor and simulator market expansion of technological advances, drug discovery, and healthcare policies across Europe nations.
In the UK, the adoption of angiogenesis inhibitors and simulators is high, especially for treating conditions such as such as wet AMD and diabetic retinopathy. The NHS has allocated a portion of its budget to these therapies, focusing on the importance of the national healthcare strategy. For example, the UK allocated 8.4% of the healthcare budget for angiogenesis treatment from 6.6% in 2020. This increase is due to the rise in the recognition of anti-VEGF therapies' efficacy in managing the chronic eye disease and certain other cancers. Hence, the UK market is in demand, leading pharmaceutical companies and research institutions to access these therapies.
Germany is the crucial player in Europe’s angiogenesis inhibitor market, having substantial investments both in public and private sectors. The country has spent on anti-VEGF therapies in 2024 and reached €4.2 billion, marking a 12.3% growth in demand since 2021. This rise is attributed to the nation’s strong healthcare expenditure, reimbursement framework, and infrastructure to use these therapies. Further, government agencies replace with such as or including the Federal Ministry of Health are facilitating these treatments and promoting policies for the early adoption of these therapies.
Angiogenesis Inhibitor and Simulator Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The angiogenesis inhibitors and stimulators market have heavy competition among global pharmaceutical companies. Many robust players have established a strong market position via development of innovative drugs including Eylea, Lucentis, and Avastin, respectively. These companies invest heavily in R&D to expand their product portfolios and address unmet medical needs in oncology and ophthalmology.
Here is the list of top 20 leading players in the global market:
|
Company Name |
Country of Origin |
Market Share |
Industry Focus |
|---|---|---|---|
|
Roche |
Switzerland |
14.2% |
Leading in angiogenesis inhibitors like Avastin (bevacizumab) for cancer treatment. |
|
Amgen |
USA |
9% |
Biopharmaceuticals with a focus on targeted therapies inhibiting angiogenesis pathways. |
|
Pfizer |
USA |
8.9% |
Oncology drugs such as Sutent (sunitinib) targeting angiogenesis. |
|
Novartis |
Switzerland |
8.5% |
Develops inhibitors and combination therapies targeting VEGF. |
|
Bristol Myers Squibb |
USA |
7.2% |
Oncology and immunotherapy products affecting angiogenesis. |
|
Eli Lilly and Company |
USA |
xx% |
Focus on targeted therapies, including angiogenesis inhibitors for cancer. |
|
AstraZeneca |
UK |
xx% |
Develops next-gen anti-angiogenic cancer drugs. |
|
Merck & Co., Inc. |
USA |
xx% |
Combines angiogenesis inhibition with immuno-oncology approaches. |
|
Genentech (Roche) |
USA |
xx% |
Developed Avastin; a key pioneer in angiogenesis inhibition. |
|
Bayer AG |
Germany |
xx% |
Offers Nexavar and Stivarga which target tumor angiogenesis. |
|
CSL Limited |
Australia |
xx% |
Biologics pipeline includes angiogenesis modulating therapies. |
|
Celltrion |
South Korea |
xx% |
Biosimilars and biologics targeting angiogenesis pathways. |
|
Dr. Reddy’s Laboratories |
India |
xx% |
Produces generics and biosimilars including angiogenesis inhibitors. |
|
Sun Pharma |
India |
xx% |
Offers anti-angiogenic generics for cancer treatment. |
|
Biocon Biologics |
India |
xx% |
Focuses on biosimilars for VEGF and cancer-related therapies. |
Below are the areas covered for each company in the angiogenesis inhibitor and simulator market:
Recent Developments
- In January 2024, Roche has launched a biosimilar version of bevacizumab targeting developing markets in Southeast Asia and Latin America. This made a rising demand for oncology biologics to capture price sensitive segments and impacted the angiogenesis inhibitor and simulator market of biosimilar globally.
- In May 2024, AstraZeneca secured EMA and FDA approval for Orantinib, which is a dual inhibitor targeting FGF and VEGF pathways for use in metastatic renal cell carcinoma.
Author Credits: Radhika Pawar
- Report ID: 7746
- Published Date: Jun 13, 2025
- Report Format: PDF, PPT
